<i>In vitro</i> activity of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against clinical isolates of non-<i>aeruginosa Pseudomonas</i>
Ceftolozane/tazobactam and ceftazidime/avibactam may be of interest as second-line β-lactams against non-carbapenemase-producing strains. Cefiderocol was highly active against NAP of our collection, especially MBL-producing isolates. Further studies are needed to correlate in vitro susceptibility of NAP to cefiderocol and clinical responses.
Authors
- Clémence Massip (ORCID: https://orcid.org/0000-0002-5193-9101)
- Pauline Floch
- Camille V. Chagneau (ORCID: https://orcid.org/0000-0002-3061-9184)
- Damien Dubois (ORCID: https://orcid.org/0000-0001-8249-8700)
- Lucie Thene
Institutions
- Université Toulouse III - Paul Sabatier (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1093/jac/dkaf067
- Citations
- 2
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.18